• Explore /
  • Poster
  • / Updated efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion gastrointestinal (GI) cancer.

Updated efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion gastrointestinal (GI) cancer.

Abstract Poster

Authors

null

Lin Shen

Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China

Lin Shen , Thierry Andre , Hyun Cheol Cheol Chung , John F. Deeken , Elena Garralda , Antoine Italiano , Serge Leyvraz , Tianshu Liu , Domnita-Ileana Burcoveanu , Robin Grugel , Chiara E. Mussi , Rui-Hua Xu , David S. Hong , Alexander E. Drilon , Jordan Berlin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02576431

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 109)

DOI

10.1200/JCO.2024.42.3_suppl.109

Abstract #

109

Poster Bd #

G13

Abstract Disclosures

Similar Posters

First Author: Jessica Jiyeong Lin

First Author: Alexander E. Drilon

First Author: David S. Hong

First Author: Maria E. Cabanillas